Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Emma Reeve

Physician Assistant, Medical Scottsdale, AZ Physician Assistant

NPI 1801374913 CMS profile 10935786

9336 E Raintree Dr Ste 150, Scottsdale, AZ 85260

Open in the dashboard

General payments

$14,724

757 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emma Reeve of Scottsdale, AZ is reported in the CMS Open Payments database as having received $14,724 across 757 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,010 148
2024 General $3,236 171
2023 General $2,828 155
2022 General $2,614 129
2021 General $2,037 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emma Reeve
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Emma Reeve were reported at $4,010. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Emma Reeve Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,037 $156 $41–$563 $132
2022 $2,614 $185 $55–$649 $149
2023 $2,828 $199 $58–$717 $160
2024 $3,236 $206 $62–$740 $164
2025 $4,010 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $2,226 23 payments
  2. Novo Nordisk Inc $1,479 164 payments
  3. Corcept Therapeutics $1,456 49 payments
  4. Lilly USA, LLC $1,444 87 payments
  5. Abbott Laboratories $949 77 payments
  6. Amgen Inc. $699 30 payments
  7. Sanofi-Aventis U.S. LLC $610 26 payments
  8. AbbVie, Inc. $549 31 payments
  9. Dexcom, Inc. $484 24 payments
  10. Mannkind Corporation $383 21 payments
  11. Other $4,445 225 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,588 750 payments
  2. Travel and Lodging $1,015 3 payments
  3. Education $62 3 payments
  4. Gift $59 1 payment
Products named General payments · program years 2021–2025
  1. MINIMED 780G $1,556 9 payments
  2. Korlym $1,456 49 payments
  3. Ozempic $1,217 139 payments
  4. RYBELSUS $1,055 132 payments
  5. FreeStyle Libre 3 $695 45 payments
  6. JARDIANCE $634 42 payments
  7. EVENITY $500 25 payments
  8. SYNTHROID $465 26 payments
  9. Dexcom G6 Transmitter $425 21 payments
  10. Prolia $424 19 payments
  11. Other $8,537 453 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

2,508

Median for Physician Assistant: 241

Drug cost

$1,367,703

Median for Physician Assistant: $4,110

Branded share of claims

60.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 321 $484,112
Jardiance Empagliflozin Brand 133 $173,828
Mounjaro Tirzepatide Brand 123 $151,502
Trulicity Dulaglutide Brand 55 $85,011
Farxiga Dapagliflozin Propanediol Brand 72 $68,670
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 53 $50,763
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 33 $43,388
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 50 $30,486
Tresiba Flextouch U-100 Insulin Degludec Brand 46 $29,917
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 31 $29,526

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $378
$378 — —
JARDIANCE
  • Lilly USA, LLC $217
  • Boehringer Ingelheim Pharmaceuticals, Inc. $69
$286 133 —
Tymlos
  • Radius Health, Inc. $163
$163 — —
Qutenza
  • Averitas Pharma Inc. $162
$162 — —
Ozempic
  • Novo Nordisk Inc $97
$97 321 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

757 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record